
Contineum Therapeutics
- Active openings
- 0
- US-based roles
- 0
- Remote-friendly
- 0
- Last updated
- None
What Contineum Therapeutics is hiring for
About Contineum Therapeutics
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
CTX-343, a Selective, Potent, Peripherally Restricted LPA Receptor 1 (LPAR1) Antagonist for Treating MASH and Other Fibrotic Liver Diseases
LPA1 receptor (LPAR1) localization in IPF tissue and functional profiling of PIPE-791, a highly selective, orally dosed LPAR1 antagonist for potential treatment of pulmonary fibrosis
CTX-343, a selective, potent, peripherally restricted LPA1 receptor (LPAR1) antagonist for IPF and other fibrosing lung diseases
Identification and Evaluation of [18F] PIPE-497, the First CNS-Penetrant PET Tracer for the Imaging of Lysophosphatidic Acid Receptor 1 in the Clinic
PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists with Distinct Lung Occupancy Profiles and Vascular Effects
LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro